OmniAb Investor Presentation Deck
Intellectual Property Advantage
PARTNERS FILING PATENTS ON OMNIAB-DERIVED ANTIBODIES CAN CREATE DIVERSE AND
DURABLE ROYALTY STREAMS AND A LENGTHY IP TAIL
Over 300 patents issued worldwide
●
• We maintain a broad intellectual property estate with multiple long
duration patent families covering each major element of our
technology platform
• Licenses are structured so that royalties are linked to the patents for
the antibodies discovered with OmniAb, thereby creating a lengthy
coverage tail
>65 patent filings by our partners claiming an OmniAb-derived antibody as
primary invention, with expiries up to 2041
Antibody Patent Applications
Filed by Partners
70
60
50
40
30
20
10
0
2014
2015
2016
2017
2018
Patents include: WO2015167293A1, WO2017020291A1, WO2017024515A1, WO2017024146A1, WO2017031104A1, WO2017053748A2, WO2017059196A2, WO2017059243A2, WO2017079121A2, WO2017178493A1, WO2017192567A1, WO2017223111A1, WO2018054241A1, US20180105600A1, WO2018057802 A1, WO2018069500A2,
WO2018091661A1, WO2018095932A1, WO2018119016A1, WO2018119246A1, WO2018162749A1, WO2019094265A1, WO2019158645A1, WO2019164891A1, WO2019165982A1, WO2019179391A1, WO2019179422A1, WO2019196868A1, WO2019202041A1, WO2019214624A1, WO2019220368A1, WO2019224711A2, WO2019224713A2,
WO2019224717A2, WO2020028479A1, WO2020093023A1, WO2020093024A2, WO20200970099A1, WO2020119719A1, WO2021194481A1, WO2020206251A1, WO2020202097A1, US10968280B2, WO2021019386A1,WO2021030488A1, WO2021044005A1, WO2021059075A1, WO2021078219A1, WO2021092196A9, WO2021089704A1,.
WO2021093764A1, WO2021093849A1, WO2021101975A1, WO2021102173A1, WO2021140222A1, WO2021154761A1, WO2021156326A1, WO2021171257A1, WO2021181366A1, WO2021185934A1, WO2021205361A1, WO2021209495A1, US20210363273A1, WO2022024024A2, WO2022048883A1, WO2022037662A1, WO2022121966A1
2019
2020
2021
27
OmniAbView entire presentation